OSR Holdings appoints Dr. Constance Höfer as Chief Scientific Officer

OSR Holdings, Inc.

Dr. Höfer appointed CSO effective March 24, 2025; oversees scientific strategy and innovation pipeline.
Over 20 years experience in oncology/immunology; previously led global programs at Merck Healthcare.
Employment agreement: $300,000 base salary plus equity compensation and customary benefits.
No family relationships with directors/officers and no reportable related-party transactions.
Appointment aims to strengthen R&D capabilities and accelerate drug development across multiple modalities.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Constance Höfer

Chief Scientific Officer

OSRH · OSR Holdings, Inc.

Effective: 2025-03-24
Filed: March 25, 2025, 7:59 PM ET

On March 24, 2025, the Board of Directors of OSR Holdings, Inc. (the “Company”) appointed Dr. Constance Höfer as the Company’s Chief Scientific Officer , effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Constance Höfer was appointed as Chief Scientific Officer at OSR Holdings, Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

On March 24, 2025, the Board of Directors of OSR Holdings, Inc. (the “Company”) appointed Dr. Constance Höfer as the Company’s Chief Scientific Officer , effective immediately.

View on SEC.gov

OSR Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001013762-25-001833

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.